Web Results

www.alkermes.com

Alkermes plc is a pharmaceutical manufacturing and biopharmaceutical company developing innovative medicines to help patients with serious chronic conditions.

www.alkermes.com/contact-us

Contact our biotech and pharmaceutical company's research, business development, technology, contract pharma services and investor/media relations departments.

www.alkermes.com/about-us/board-of-directors

The Alkermes Inc. Board of Directors provides significant leadership and guidance within the biopharmaceutical industry. ... Wendy L. Dixon, Ph.D. Dr. Dixon ... Mr. Mitchell is a graduate of College of the Holy Cross (B.A. Economics) and Northeastern University (M.S. Accounting) and he is also a Certified Public Accountant.

markets.businessinsider.com/stock/Alkermes_1-Quote

Alkermes Plc operates as a biopharmaceutical company. It engages in the development, manufacture, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, ...

investor.alkermes.com/mobile.view?c=92211&v=203&d=1&id=2004543

Jan 7, 2015 ... 7, 2015-- Alkermes plc (NASDAQ: ALKS) today announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose- ranging stage .... 2Regier D, Farmer M, Rae D, Locke B, Keith S, Judd L, Goodwin F. Comorbidity of Mental Disorders With Alcohol and Other Drug Abuse.

quotes.wsj.com/ALKS

Alkermes Named a Top Place to Work by The Boston Globe. Press Release. 11/ 16/17; Press Release. Lifshitz & Miller LLP Announces Investigation of Acorda Therapeutics, Inc., Alkermes plc, ASB Financial Corp., CalAtlantic Group, Capella Education Company, INC Research Holdings, Inc. and YuMe, Inc. Press Release .

seekingalpha.com/filing/3516980

Apr 27, 2017 ... UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. Form 10-Q. (Mark One). ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2017. OR. ☐ TRANSITION ...

seekingalpha.com/filing/3416616

Feb 17, 2017 ... Our existing indebtedness is secured by a first priority lien on substantially all of the combined company assets and properties of Alkermes plc and most of its subsidiaries, which serve as guarantors. The agreements governing Term Loan B-1 include a number of restrictive covenants that, among other ...

seekingalpha.com/article/4046311-alkermes-plc-alks-q4-2016-results-earnings-call-transcript

Feb 15, 2017 ... Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question- and-answer session. Please note, this conference is being ...